As many as 15.44 lakh shares of the company, or 1.41% of its equity, worth ₹180 crore changed hands at ₹1,170 per share via block deals.
The official buyers and sellers are not yet known.
At the end of the June quarter promoter entities held 59.07% stake in the company, while public shareholders held 40.83%, as per data available on the stock exchanges.
Earlier this month, the company said it has secured a chemical supply contract with a global industrial major, paving the way for a long-term six-year partnership.
While Anupam Rasayan did not name the company, it said it was awarded the order by a major specialty metal manufacturer headquartered in the US.
The company told CNBC-TV18 last month that it expects its consolidated revenue growth to be more than 30% this fiscal, up from its previous guidance of 20-25%. Deputy CFO Vishal Thakkar told CNBC-TV18 that the growth is largely volume-driven, with the pharma and polymer businesses continuing to support the performance.
The company reported a profit of ₹38.6 crore in the June quarter, up 14% from the previous year’s ₹34 crore. Its revenue increased 35% to ₹655 crore from ₹485.8 crore.
The company’s earnings before interest, taxes, depreciation and amortization (EBITDA) increased 31% to ₹162.4 crore from ₹124.3 crore but its margin contracted to 25.8% from 25.6% in the year-ago period.
Shares of Anupam Rasayan declined 4.8% to hit an intraday low of ₹1,150.1 apiece on Monday. However, the stock later recovered from its intraday low and was trading 1.6% lower at ₹1,188 apiece at 10.03 am. It has declined 4.4% in the past month and is down 10.4% this year, so far.
Also Read: This defence stock could rise 55% in a ‘bull case’ scenario, predicts Motilal Oswal